Sepsis expands a CD39

Adenosine / immunology Animals Antigens, CD / immunology Apyrase / immunology Cellular Reprogramming / immunology Immune Tolerance / immunology Macrophages / immunology Mice Plasma Cells / immunology Receptor, Adenosine A2A / immunology Sepsis / immunology
A2aR B cells CD39 IL-10 adenosine immunosuppression macrophages plasmablast sepsis

Journal

Immunity
ISSN: 1097-4180
Titre abrégé: Immunity
Pays: United States
ID NLM: 9432918

Informations de publication

Date de publication:
14 09 2021
Historique:
received: 05 08 2020
revised: 14 09 2020
accepted: 06 08 2021
pubmed: 3 9 2021
medline: 10 11 2021
entrez: 2 9 2021
Statut: ppublish

Résumé

Sepsis results in elevated adenosine in circulation. Extracellular adenosine triggers immunosuppressive signaling via the A2a receptor (A2aR). Sepsis survivors develop persistent immunosuppression with increased risk of recurrent infections. We utilized the cecal ligation and puncture (CLP) model of sepsis and subsequent infection to assess the role of adenosine in post-sepsis immune suppression. A2aR-deficient mice showed improved resistance to post-sepsis infections. Sepsis expanded a subset of CD39

Identifiants

DOI: 10.1016/j.immuni.2021.08.005 PMID: 34473957
pubmed: 34473957
pii: S1074-7613(21)00335-6
doi: 10.1016/j.immuni.2021.08.005
pii:
doi:

Substances chimiques

Adora2a protein, mouse 0
Antigens, CD 0
Receptor, Adenosine A2A 0
Apyrase EC 3.6.1.5
CD39 antigen EC 3.6.1.5
Adenosine K72T3FS567

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2024-2041.e8

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests The authors declare no competing interests.

Auteurs

Daniele Carvalho Nascimento (DC)

Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP 14049-900, Brazil; Center for Research in Inflammatory Diseases, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP 14049-900, Brazil; CNRS, UMR7355, Orleans, 45071, France. Electronic address: danielecbn@usp.br.

Paula Ramos Viacava (PR)

Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP 14049-900, Brazil; Center for Research in Inflammatory Diseases, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP 14049-900, Brazil.

Raphael Gomes Ferreira (RG)

Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP 14049-900, Brazil; Center for Research in Inflammatory Diseases, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP 14049-900, Brazil.

Marina Alves Damaceno (MA)

Department of Biomolecular Sciences, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP 14049-900, Brazil.

Annie Rocío Piñeros (AR)

Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP 14049-900, Brazil; Center for Research in Inflammatory Diseases, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP 14049-900, Brazil.

Paulo Henrique Melo (PH)

Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP 14049-900, Brazil; Center for Research in Inflammatory Diseases, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP 14049-900, Brazil.

Paula Barbim Donate (PB)

Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP 14049-900, Brazil; Center for Research in Inflammatory Diseases, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP 14049-900, Brazil.

Juliana Escher Toller-Kawahisa (JE)

Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP 14049-900, Brazil; Center for Research in Inflammatory Diseases, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP 14049-900, Brazil.

Daniel Zoppi (D)

Department of Internal Medicine, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP 14049-900, Brazil.

Flávio Protásio Veras (FP)

Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP 14049-900, Brazil; Center for Research in Inflammatory Diseases, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP 14049-900, Brazil.

Raphael Sanches Peres (RS)

Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP 14049-900, Brazil; Center for Research in Inflammatory Diseases, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP 14049-900, Brazil.

Luísa Menezes-Silva (L)

Institute of Biomedical Sciences, University of São Paulo, São Paulo, SP 05508-000, Brazil.

Diego Caetité (D)

Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP 14049-900, Brazil; Center for Research in Inflammatory Diseases, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP 14049-900, Brazil.

Antonio Edson Rocha Oliveira (AER)

Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, SP 05508-000, Brazil.

Ícaro Maia Santos Castro (ÍMS)

Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, SP 05508-000, Brazil.

Gilles Kauffenstein (G)

UMR INSERM 1260, Regenerative NanoMedicine, University of Strasbourg, Strasbourg 60026, France.

Helder Imoto Nakaya (HI)

Hospital Israelita Albert Einstein, São Paulo, 05620-900, Brazil.

Marcos Carvalho Borges (MC)

Department of Internal Medicine, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP 14049-900, Brazil.

Dario Simões Zamboni (DS)

Center for Research in Inflammatory Diseases, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP 14049-900, Brazil; Department of Cell Biology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP 14049-900, Brazil.

Denise Morais Fonseca (DM)

Institute of Biomedical Sciences, University of São Paulo, São Paulo, SP 05508-000, Brazil.

Jonas Augusto Rizzato Paschoal (JAR)

Department of Biomolecular Sciences, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP 14049-900, Brazil.

Thiago Mattar Cunha (TM)

Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP 14049-900, Brazil; Center for Research in Inflammatory Diseases, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP 14049-900, Brazil.

Valerie Quesniaux (V)

CNRS, UMR7355, Orleans, 45071, France; Experimental and Molecular Immunology and Neurogenetics, University of Orleans, Orleans 45071, France.

Joel Linden (J)

Division of Nephrology, Center for Immunity, Inflammation and Regenerative Medicine University of Virginia School of Medicine, Charlottesville, VA 22903, USA.

Fernando Queíroz Cunha (FQ)

Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP 14049-900, Brazil; Center for Research in Inflammatory Diseases, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP 14049-900, Brazil.

Bernhard Ryffel (B)

CNRS, UMR7355, Orleans, 45071, France; Experimental and Molecular Immunology and Neurogenetics, University of Orleans, Orleans 45071, France.

José Carlos Alves-Filho (JC)

Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP 14049-900, Brazil; Center for Research in Inflammatory Diseases, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP 14049-900, Brazil. Electronic address: jcafilho@usp.br.

Articles similaires

Evaluating the efficacy of telesurgery with dual console SSI Mantra Surgical Robotic System: experiment on animal model and clinical trials.

Sudhir Prem Srivastava, Vishwajyoti Pascual Srivastava, Avinesh Singh et al.
1.00
Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell

FBXO22 inhibits colitis and colorectal carcinogenesis by regulating the degradation of the S2448-phosphorylated form of mTOR.

Minle Li, Xuan Chen, Pengfei Qu et al.
1.00
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice

Use of organic material provided by an automatic enrichment device by weaner pigs and its influence on tail lesions.

Philipp Heseker, Jeanette Probst, Stefanie Ammer et al.
1.00
Animals Tail Swine Behavior, Animal Animal Husbandry

Classifications MeSH

questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Nucléosides › Ribonucléosides › Adénosine › Sepsis expands a CD39
questionsmedicales.fr › Eucaryotes › Animaux › Sepsis expands a CD39
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Antigènes de différenciation › Antigènes CD › Sepsis expands a CD39
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Hydrolases › Acid anhydride hydrolases › Apyrase › Sepsis expands a CD39
questionsmedicales.fr › Phénomènes génétiques › Reprogrammation cellulaire › Sepsis expands a CD39
questionsmedicales.fr › Phénomènes du système immunitaire › Immunomodulation › Tolérance immunitaire › Sepsis expands a CD39
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Phagocytes › Macrophages › Sepsis expands a CD39
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Sepsis expands a CD39
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes B › Plasmocytes › Sepsis expands a CD39
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs aux neuromédiateurs › Récepteurs purinergiques › Récepteurs purinergiques P1 › Récepteurs A2 à l'adénosine › Récepteur A2A à l'adénosine › Sepsis expands a CD39
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Inflammation › Sepsie › Sepsis expands a CD39